Comparable stake leader
Nantahala Capital Management, LLC
SEC ownership of Apyx Medical Corp
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0000719135.
Disclosed value leader
ROYCE & ASSOCIATES LP
Comparable rows
50/50
Latest evidence
30 Jun 2026
- Public ticker
- APYX on Nasdaq
- Parsed ownership sources
-
13D/G and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Nantahala Capital Management, LLC
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Nantahala Capital Management, LLC
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0000719135
- Issuer location
- Clearwater, FL
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Apyx Medical Corp (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Nantahala Capital Managem...
Disclosed value leader
ROYCE & ASSOCIATES LP
Comparable rows
50/50
Latest evidence
30 Jun 2026
13D/G
13F
Lead comparable stake: 10%
13D/G row: Nantahala Capital Management, LLC
Showing 1-8 of 50 holder rows.
Quick read
Nantahala Capital Management, LLC leads the comparable SEC ownership view at 10%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Nantahala Capital Management, LLC's linked filing trail.
Comparable ownership
Top 5
Nantahala Capital Management, LLC
10%
ROYCE & ASSOCIATES LP
7.8%
Archon Capital Management LLC
6.7%
VANGUARD CAPITAL MANAGEMENT LLC
3.7%
AIGH Capital Management LLC
2.6%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Nantahala Capital Management, LLC |
13D/G
13F
Company
|
10%
|
$14,394,468
4,112,705 shares
|
+$2,168,145 | 31 Dec 2025 |
| ROYCE & ASSOCIATES LP |
13D/G
13F
Company
|
7.8%
|
$14,700,547
3,274,064 shares
|
+$3,731,320 | 30 Jun 2026 |
| Archon Capital Management LLC |
13F
Company
|
6.7%
|
$10,298,506
2,790,923 shares
|
— | 31 Mar 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13F
Company
|
3.7%
|
$5,738,954
1,555,272 shares
|
— | 31 Mar 2026 |
| AIGH Capital Management LLC |
13F
Company
|
2.6%
|
$4,077,340
1,104,970 shares
|
— | 31 Mar 2026 |
| Silverberg Bernstein Capital Management LLC |
13F
Company
|
2.5%
|
$3,841,548
1,041,070 shares
|
— | 31 Mar 2026 |
| ESSEX INVESTMENT MANAGEMENT CO LLC |
13F
Company
|
2.2%
|
$3,326,159
901,398 shares
|
— | 31 Mar 2026 |
| COMMONWEALTH EQUITY SERVICES, LLC |
13F
Company
|
1.5%
|
$2,395,040
649,061 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 02 Aug 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-14 of 14 reporting-owner rows connected to Apyx Medical Corp. Open a relationship link for the CIK-to-CIK filing trail.
Rows
14
Largest Forms 3/4/5 holder
Moshe Citronowicz
Net 12M change
$0
Latest report
30 Jun 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Moshe Citronowicz | Sr. V.P. of Operations | $1,895,055 | Mixed | 11 Jun 2026 | ||
| Lawrence J. Waldman | Director | $184,045 | Mixed | 30 Jun 2026 | ||
| Shawn David Roman | Chief Operating Officer | $60,763 | Mixed | 15 Jun 2026 | ||
| Matthew C. Hill | Chief Financial Officer | $9,605 | Filing P/S | 11 Jun 2026 | ||
| Minnie Baylor-Henry | Director | Mixed | 11 Jun 2026 | |||
| Tara Semb | Chief Financial Officer | Mixed | 11 Jan 2023 | |||
| Todd Hornsby | Executive Vice President | Mixed | 10 Jan 2024 | |||
| Michael Geraghty | Director | Mixed | 08 Aug 2024 | |||
| Craig A. Swandal | Director | Mixed | 08 Aug 2024 | |||
| Wendy Lauren Levine | Director | Mixed | 11 Jun 2026 | |||
| Andrew Makrides | Director | Mixed | 10 Aug 2023 | |||
| Charles D. Goodwin II | Chief Executive Officer, Director | Mixed | 11 Jun 2026 | |||
| Stavros G. Vizirgianakis | Director | Mixed | 11 Jun 2026 | |||
| John C. Andres | Director | Mixed | 08 Aug 2024 |
Recent insider transactions for Apyx Medical Corp
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Lawrence J. Waldman | APYX | Common Stock | Tax liability | -29% | -5,024 | 12,314 | 30 Jun 2026 | By SLAT | ||
| Lawrence J. Waldman | APYX | Common Stock | Options Exercise | 224.8% | 12,000 | 17,338 | 30 Jun 2026 | By SLAT | ||
| Lawrence J. Waldman | APYX | Stock option (right to buy) | Options Exercise | -100% | -12,000 | 0 | 30 Jun 2026 | By SLAT | ||
| Shawn David Roman | APYX | Common Stock | Tax liability | -39% | -10,533 | 16,467 | 15 Jun 2026 | By The Roman Family Revocable Trust | ||
| Shawn David Roman | APYX | Common Stock | Options Exercise | 15,000 | 15,000 | 15 Jun 2026 | By The Roman Family Revocable Trust | |||
| Shawn David Roman | APYX | Stock option (right to buy) | Options Exercise | -100% | -15,000 | 0 | 15 Jun 2026 | Direct | ||
| Wendy Lauren Levine | APYX | Stock Option (Option to Buy) | Award | 50,000 | 50,000 | 11 Jun 2026 | Direct | |||
| Stavros G. Vizirgianakis | APYX | Restricted Stock Units | Award | 25.8% | 450,000 | 2,196,191 | 11 Jun 2026 | Direct | ||
| Charles D. Goodwin II | APYX | Stock Option (Option to Buy) | Award | 213,948 | 213,948 | 11 Jun 2026 | Direct | |||
| Shawn David Roman | APYX | Stock Option (Option to Buy) | Award | 88,044 | 88,044 | 11 Jun 2026 | Direct | |||
| Minnie Baylor-Henry | APYX | Stock Option (Option to Buy) | Award | 50,000 | 50,000 | 11 Jun 2026 | Direct | |||
| Lawrence J. Waldman | APYX | Stock Option (Option to Buy) | Award | 50,000 | 50,000 | 11 Jun 2026 | Direct | |||
| Matthew C. Hill | APYX | Stock Option (Option to Buy) | Award | 132,066 | 132,066 | 11 Jun 2026 | Direct | |||
| Moshe Citronowicz | APYX | Stock Option (Option to Buy) | Award | 63,392 | 63,392 | 11 Jun 2026 | Direct | |||
| Moshe Citronowicz | APYX | Common Stock | Options Exercise | 8.11% | 37,000 | 493,504 | 15 Mar 2026 | Direct | ||
| Moshe Citronowicz | APYX | Stock option (right to buy) | Options Exercise | -100% | -37,000 | 0 | 15 Mar 2026 | Direct | ||
| Shawn David Roman | APYX | Common Stock | Options Exercise | 12,000 | 12,000 | 27 Jan 2026 | By The Roman Family Revocable Trust | |||
| Shawn David Roman | APYX | Stock option (right to buy) | Options Exercise | -100% | -12,000 | 0 | 27 Jan 2026 | Direct |
* marks a reported price that did not pass the local price check.